The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: Role in receptor-binding activity

Journal of Lipid Research

Volumn 39, Issue 6, 1998, Pages 1173-1180

  Dong, Li Ming ^a   Innerarity, Thomas L ^a,b   Arnold, Kay S ^a   Newhouse, Yvonne M ^a   Weisgraber, Karl H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carboxyl terminal truncations; Site directed mutagenesis

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN VARIANT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; BINDING SITES; BINDING, COMPETITIVE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; VARIATION (GENETICS);

EID: 0031864142     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Weisgraber, K. H., S. C. Rall, Jr., and R. W. Mahley. 1981. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256: 9077-9083.
2. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
3. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
4. Weisgraber, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45: 249-302.
5. Mahley, R. W., and S. C. Rail, Jr. 1995. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease. 7th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1953-1980.
6. Havekes, L., E. de Wit, J. G. Leuven, E. Klasen, G. Utermann, W. Weber, and U. Beisiegel. 1986. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum. Genet. 73: 157-163.
7. Wardell, M. R., K. H. Weisgraber, L. M. Havekes, and S. C. Rall, Jr. 1989. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J. Biol. Chem. 264: 21205-21210.
8. Aggerbeck, L. P., J. R. Wetterau, K. H. Weisgraber, G-S. C. Wu, and F. T. Lindgren. 1988. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J. Biol. Chem. 263: 6249-6258.
9. Wetterau, J. R., L. P. Aggerbeck, S. C. Rail, Jr., and K. H. Weisgraber. 1988. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263: 6240-6248.
10. Innerarity, T. L., E. J. Friedlander, S. C. Rall, Jr., K. H. Weisgraber, and R. W. Mahley. 1983. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J. Biol. Chem. 258: 12341-12347.
11. Lalazar, A., K. H. Weisgraber, S. C. Rall, Jr., H. Giladi, T. L. Innerarity, A. Z. Levanon, J. K. Boyles, B. Amit, M. Gorecki, R. W. Mahley, and T. Vogel. 1988. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263: 3542-3545.
12. Weisgraber, K., H., T. L. Innerarity, K. J. Harder, R. W. Mahley, R. W. Milne, Y. L. Marcel, and J. T. Sparrow. 1983. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J. Biol. Chem. 258: 12348-12354.
13. Wilson, C., T. Mau, K. H. Weisgraber, M. R. Wardell, R. W. Mahley, and D. A. Agard. 1994. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure. 2: 713-718.
14. Innerarity, T. L., K. H. Weisgraber, K. S. Arnold, S. C. Rall, Jr., and R. W. Mahley. 1984. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J. Biol. Chem. 259: 7261-7267.
15. Dong, L-M., S. Parkin, S. D. Trakhanov, B. Rupp, T. Simmons, K. S. Arnold, Y. M. Newhouse, T. L. Innerarity, and K. H. Weisgraber. 1996. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat. Struct. Biol. 3: 718-722.
16. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene, 67: 31-40.
17. Dong, L-M., C. Wilson, M. R. Wardell, T. Simmons, R. W. Mahley, K. H. Weisgraber, and D. A. Agard. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269: 22358-22365.
18. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74: 5463-5467.
19. Rall, S. C., Jr., K. H. Weisgraber, and R. W. Mahley. 1986. Isolation and characterization of apolipoprotein E. Methods Enzymol. 128: 273-287.
20. Innerarity, T. L., R. W. Mahley, K. H. Weisgraber, and T. P. Bersot. 1978. Apoprotein (E-A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E-A-II) complex. J. Biol. Chem. 253: 6289-6295.
21. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
22. Innerarity, T. L., R. E. Pitas, and R. W. Mahley. 1979. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J. Biol. Chem. 254: 4186-4190.
23. Pittman, R. C., C. K. Glass, D. Atkinson, and D. M. Small. 1987. Synthetic high density lipoprotein particles. Application to studies of the apoprotein specificity for selective uptake of cholesterol esters. J. Biol. Chem. 262: 2435-2442.
24. Spooner, P. J. R., S. B. Clark, D. L. Gantz, J. A. Hamilton, and D. M. Small. 1988. The ionization and distribution behavior of oleic acid in chylomicrons and chylomicron-like emulsion particles and the influence of serum albumin. J. Biol. Chem. 263: 1444-1453.
25. Bellosta, S., B. P. Nathan, M. Orth, L-M. Dong, R. W. Mahley, and R. E. Pitas. 1995. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270: 27063-27071.
26. Simmons, T., Y. M. Newhouse, K. S. Arnold, T. L. Innerarity, and K. H. Weisgraber. 1997. Human low density lipoprotein fragment successful refolding of a functionally active ligand-binding domain produced in Escherichia coli. J. Biol. Chem. 272: 25531-25536.
27. Pitas, R. E., T. L. Innerarity, and R. W. Mahley. 1980. Cell surface receptor binding of phospholipid-protein complexes containing different ratios of receptor-active and -inactive E apoprotein. J. Biol. Chem. 255: 5454-5460.
28. Westerlund, J. A., and K. H. Weisgraber. 1993. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J. Biol. Chem. 268: 15745-15750.
29. Fazio, S., Y. Horie, K. H. Weisgraber, L. M. Havekes, and S. C. Rall, Jr. 1993. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma. J. Lipid Res. 34: 447-453.
30. Dong, L-M., and K. H. Weisgraber. 1996. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol Chem. 271: 19053-19057.
31. Horie, Y., S. Fazio, J. R. Westerlund, K. H. Weisgraber, and S. C. Rall, Jr. 1992. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267: 1962-1968.
32. Innerarity, T. L., D. Y Hui, T. P. Bersot, and R. W. Mahley. 1986. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. Adv. Exp. Med. Biol. 201: 273-288.
33. Wilson, C., M. R. Wardell, K. H. Weisgraber, R. W. Mahley, and D. A. Agard. 1991. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 252:1817-1822.